Advertisement

Survival and Growth of Prostate Cancer Cells in the Bone: Role of the Alpha-Receptor for Platelet-Derived Growth Factor in Supporting Early Metastatic Foci

  • Qingxin Liu
  • Yun Zhang
  • Danielle Jernigan
  • Alessandro Fatatis
Chapter

Abstract

Skeletal dissemination is by far the most feared complication of prostate cancer and the main cause of patients’ demise. Today, 85% of patients are diagnosed with prostate cancer in the absence of clinically evident secondary tumors. However, a significant number of these patients will eventually develop the advanced form of the disease and present with skeletal metastases. A definitive, curative treatment for bone metastatic disease is still an unmet clinical need and the current standard of care relies on merely palliative measures.

There is vast consensus on the fact that cancer cells that spread to the skeleton need to find favorable local conditions to survive and grow. Indeed, those cells that fail to receive appropriate support will either remain dormant or undergo cell death, thereby exerting a negligible clinical impact on patients’ quality of life and overall survival. Significant efforts have been made to identify the cellular events as well as signaling molecules and mechanisms implicated in the growth of cancer cells in the bone marrow. Pre-clinical and clinical studies have investigated the role exerted by the receptors for Platelet-Derived Growth Factor (PDGFRs) in promoting skeletal metastases. Interestingly, the alpha isoform of PDGFR (PDGFRα) appears to be directly implicated in the initial colonization of the skeleton, a step of metastatic progression that might have been significantly overlooked.

Keywords

Prostate Cancer Prostate Cancer Cell Zoledronic Acid Metastatic Lesion Circulate Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gupta GP, Massagué J (2006) Cancer metastasis: building a framework. Cell 127:679–695PubMedCrossRefGoogle Scholar
  2. 2.
    Coghlin C, Murray GI (2010) Current and emerging concepts in tumour metastasis. J Pathol 222:1–15PubMedCrossRefGoogle Scholar
  3. 3.
    Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564PubMedCrossRefGoogle Scholar
  4. 4.
    Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11(2):123–134.PubMedCrossRefGoogle Scholar
  5. 5.
    Al-Mehdi AB, Tozawa K, Fisher AB et al (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 6:100–102PubMedCrossRefGoogle Scholar
  6. 6.
    Alix-Panabières C, Riethdorf S, Pantel K (2008) Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res: an official journal of the American Association for Cancer Research 14:5013–5021PubMedCrossRefGoogle Scholar
  7. 7.
    Glinskii O, Huxley V, Glinsky G et al (2005) Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 7:522–527PubMedCrossRefGoogle Scholar
  8. 8.
    Nguyen DX, Bos PD, Massagué J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284PubMedCrossRefGoogle Scholar
  9. 9.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMedCrossRefGoogle Scholar
  10. 10.
    Shibue T, Weinberg RA (2011) Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol 21:99–106PubMedCrossRefGoogle Scholar
  11. 11.
    Weinberg RA (2008) The many faces of tumor dormancy. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 116:548–551PubMedGoogle Scholar
  12. 12.
    Lin H, Balic M, Zheng S et al (2011) Disseminated and circulating tumor cells: role in effective cancer management. Crit Rev Oncol Hematol 77:1–11PubMedCrossRefGoogle Scholar
  13. 13.
    Cawthorn TR, Amir E, Broom R et al (2009) Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis 26:935–943PubMedCrossRefGoogle Scholar
  14. 14.
    Roodman GD (2007) Bone-breaking cancer treatment. Nat Med 13:25–26PubMedCrossRefGoogle Scholar
  15. 15.
    Buijs JT, van der Pluijm G (2009) Osteotropic cancers: from primary tumor to bone. Cancer Lett 273:177–193PubMedCrossRefGoogle Scholar
  16. 16.
    Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664PubMedCrossRefGoogle Scholar
  17. 17.
    Kingsley LA, Fournier PG, Chirgwin JM et al (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609–2617PubMedCrossRefGoogle Scholar
  18. 18.
    Cheville JC, Tindall D, Boelter C et al (2002) Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 95:1028–1036PubMedCrossRefGoogle Scholar
  19. 19.
    Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718–729PubMedCrossRefGoogle Scholar
  20. 20.
    Lee RJ, Saylor PJ, Smith MR (2011) Treatment and prevention of bone complications from prostate cancer. Bone 48:88–95PubMedCrossRefGoogle Scholar
  21. 21.
    Jones DH, Nakashima T, Sanchez OH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692–696PubMedCrossRefGoogle Scholar
  22. 22.
    Saad F, Schulman CC (2004) Role of bisphosphonates in prostate cancer. Eur Urol 45:26–34PubMedCrossRefGoogle Scholar
  23. 23.
    Bouganim N, Clemons MJ (2011) Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol 7:381–383PubMedCrossRefGoogle Scholar
  24. 24.
    Nyambo R, Cross N, Lippitt J et al (2004) Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 19:1712–1721PubMedCrossRefGoogle Scholar
  25. 25.
    Corey E, Brown LG, Kiefer JA et al (2005) Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65:1710–1718PubMedCrossRefGoogle Scholar
  26. 26.
    Canon JR, Roudier M, Bryant R et al (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:119–129PubMedCrossRefGoogle Scholar
  27. 27.
    Lee Y-P, Schwarz EM, Davies M et al (2002) Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62:5564–5570PubMedGoogle Scholar
  28. 28.
    Corey E, Brown LG, Quinn JE et al (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research. 9:295–306PubMedGoogle Scholar
  29. 29.
    Thudi NK, Martin CK, Nadella MVP et al (2008) Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. The Prostate 68:1116–1125PubMedCrossRefGoogle Scholar
  30. 30.
    Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174PubMedCrossRefGoogle Scholar
  31. 31.
    Bagi CM (2005) Targeting of therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 57:995–1010PubMedCrossRefGoogle Scholar
  32. 32.
    Coleman RE, Guise T, Lipton A et al (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14:6387–6395PubMedCrossRefGoogle Scholar
  33. 33.
    Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468PubMedCrossRefGoogle Scholar
  34. 34.
    Stopeck AT, Lipton A, Body J-J et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139PubMedCrossRefGoogle Scholar
  35. 35.
    van der Pluijm G, Que I, Sijmons B et al (2005) Interference with the microenviron­mental support impairs the de novo formation of bone metastases in vivo. Cancer Res 65:7682–7690PubMedGoogle Scholar
  36. 36.
    Clarke NW, Hart CA, Brown MD (2009) Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 11:57–67PubMedCrossRefGoogle Scholar
  37. 37.
    Russell M, Jamieson W, Dolloff N et al (2009) The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 28:412–421PubMedCrossRefGoogle Scholar
  38. 38.
    Ohmori K, Matsui H, Yasuda T et al (1997) Evaluation of the prognosis of cancer patients with metastatic bone tumors based on serial bone scintigrams. Jpn J Clin Oncol 27:263–267PubMedCrossRefGoogle Scholar
  39. 39.
    Fidler I (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRefGoogle Scholar
  40. 40.
    Mundy GR (2000) Structure and physiology of the normal skeleton. In: Robert D, Rubens GRM (ed) Cancer and the skeleton, 3rd edn. London, UK: Informa Healthcare, pp 1–19Google Scholar
  41. 41.
    Zhang S, Wang J, Bilen M et al (2009) Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clin Exp Metastasis 26(8):993–1004PubMedCrossRefGoogle Scholar
  42. 42.
    Shiozawa Y, Pedersen EA, Havens AM et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121(4):1298–1312PubMedCrossRefGoogle Scholar
  43. 43.
    Bussard KM, Venzon DJ, Mastro AM (2010) Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J Cell Biochem 111(5):1138–1148PubMedCrossRefGoogle Scholar
  44. 44.
    Bidard F-C, Pierga J-Y, Vincent-Salomon A et al (2008) A “class action” against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev 27:5–10PubMedCrossRefGoogle Scholar
  45. 45.
    Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66:11089–11093PubMedCrossRefGoogle Scholar
  46. 46.
    Kaplan RN, Psaila B, Lyden D (2007) Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med 13:72–81PubMedCrossRefGoogle Scholar
  47. 47.
    Fidler I, Poste G (2008) The “seed and soil” hypothesis revisited. Lancet Oncol 9:808PubMedCrossRefGoogle Scholar
  48. 48.
    Chott A, Sun Z, Morganstern D et al (1999) Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155:1271–1279PubMedCrossRefGoogle Scholar
  49. 49.
    Fudge K, Wang CY, Stearns ME (1994) Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta-receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 7:549–554PubMedGoogle Scholar
  50. 50.
    Dolloff N, Shulby S, Nelson A et al (2005) Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene 24:6848–6854PubMedCrossRefGoogle Scholar
  51. 51.
    Kamb A, Wee S, Lengauer C (2007) Why is cancer drug discovery so difficult? Nat Rev Drug Discov 6:115–120PubMedCrossRefGoogle Scholar
  52. 52.
    Yang D (2000) Platelet-derived growth factor (PDGF)-AA: a self-imposed cytokine in the proliferation of human fetal osteoblasts. Cytokine 12:1271–1274PubMedCrossRefGoogle Scholar
  53. 53.
    Dolloff N, Russell MR, Loizos N et al (2007) Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res 67:555–562PubMedCrossRefGoogle Scholar
  54. 54.
    Russell MR, Liu Q, Lei H et al (2010) The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-­independent mechanisms. Cancer Res 70:4195–4203PubMedCrossRefGoogle Scholar
  55. 55.
    Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316PubMedGoogle Scholar
  56. 56.
    Fredriksson L, Li H, Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15:197–204PubMedCrossRefGoogle Scholar
  57. 57.
    Kazlauskas A, Cooper JA (1989) Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell 58:1121–1133PubMedCrossRefGoogle Scholar
  58. 58.
    Bishayee S, Majumdar S, Khire J et al (1989) Ligand-induced dimerization of the platelet-derived growth factor receptor. Monomer-dimer interconversion occurs independent of receptor phosphorylation. J Biol Chem 264:11699–11705PubMedGoogle Scholar
  59. 59.
    Baxter RM, Secrist JP, Vaillancourt RR et al (1998) Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events. J Biol Chem 273:17050–17055PubMedCrossRefGoogle Scholar
  60. 60.
    Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905–2927PubMedCrossRefGoogle Scholar
  61. 61.
    Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501PubMedCrossRefGoogle Scholar
  62. 62.
    Luo J, Manning B, Cantley L (2003) Targeting the PI3K-Akt pathway in human cancer Rationale and promise. Cancer Cell 4:257–262PubMedCrossRefGoogle Scholar
  63. 63.
    Chang F, Lee JT, Navolanic PM et al (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590–603PubMedCrossRefGoogle Scholar
  64. 64.
    Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19:2435–2444PubMedGoogle Scholar
  65. 65.
    Chang F, Steelman LS, Lee JT et al (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263–1293PubMedCrossRefGoogle Scholar
  66. 66.
    Berridge M, Bootman M, Roderick HL (2003) Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4:517–529PubMedCrossRefGoogle Scholar
  67. 67.
    Gelderloos JA, Rosenkranz S, Bazenet C et al (1998) A role for Src in signal relay by the platelet-derived growth factor alpha receptor. J Biol Chem 273:5908–5915PubMedCrossRefGoogle Scholar
  68. 68.
    DeMali KA, Godwin SL, Soltoff SP et al (1999) Multiple roles for Src in a PDGF-stimulated cell. Exp Cell Res 253:271–279PubMedCrossRefGoogle Scholar
  69. 69.
    Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470–480PubMedCrossRefGoogle Scholar
  70. 70.
    Im E, Kazlauskas A (2007) Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J Biol Chem 282:29122–29129PubMedCrossRefGoogle Scholar
  71. 71.
    Betsholtz C (2004) Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15:215–228PubMedCrossRefGoogle Scholar
  72. 72.
    Tallquist M, Kazlauskas A (2004) PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15:205–213PubMedCrossRefGoogle Scholar
  73. 73.
    Hoch RV (2003) Roles of PDGF in animal development. Dev Suppl 130:4769–4784Google Scholar
  74. 74.
    Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312PubMedCrossRefGoogle Scholar
  75. 75.
    Yarden Y, Escobedo JA, Kuang WJ et al (1986) Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 323:226–232PubMedCrossRefGoogle Scholar
  76. 76.
    Von Mehren M (2004) Targeted therapy with imatinib: hits and misses? J Clin Oncol 23:8–10CrossRefGoogle Scholar
  77. 77.
    George DJ (2002) Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 60:115–121; ­discussion 122PubMedCrossRefGoogle Scholar
  78. 78.
    Uehara H, Kim S, Karashima T et al (2003) Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95:458PubMedCrossRefGoogle Scholar
  79. 79.
    Kim SJ, Uehara H, Yazici S et al (2006) Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98:783–793PubMedCrossRefGoogle Scholar
  80. 80.
    Catena R, Luis-Ravelo D, Antón I et al (2011) PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Cancer Res 71:164–174PubMedCrossRefGoogle Scholar
  81. 81.
    Rao K, Goodin S, Levitt M et al (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62:115–122PubMedCrossRefGoogle Scholar
  82. 82.
    Lin A, Rini B, Weinberg V et al (2006) A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98:763–769PubMedCrossRefGoogle Scholar
  83. 83.
    Shah GD, Loizos N, Youssoufian H et al (2010) Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α. Cancer 116:1018–1026PubMedCrossRefGoogle Scholar
  84. 84.
    Loizos N, Xu Y, Huber J et al (2005) Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 4:369–379PubMedGoogle Scholar
  85. 85.
    Russell MR, Liu Q, Fatatis A (2010) Targeting the alpha receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res 16:5002–5010PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Qingxin Liu
    • 1
  • Yun Zhang
    • 1
  • Danielle Jernigan
    • 1
  • Alessandro Fatatis
    • 1
    • 2
  1. 1.Department of Pharmacology and PhysiologyDrexel University, College of MedicinePhiladelphiaUSA
  2. 2.Department of Pathology and Laboratory MedicineDrexel University, College of MedicinePhiladelphiaUSA

Personalised recommendations